BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

结合 医学 药品 抗体-药物偶联物 打开标签 临床研究阶段 抗体 双特异性抗体 肿瘤科 药理学 癌症研究 内科学 单克隆抗体 临床试验 免疫学 数学 数学分析
作者
Yuxiang Ma,Yan Huang,Yuanyuan Zhao,Shen Zhao,Jinhui Xue,Yunpeng Yang,Wen‐Feng Fang,Ye Guo,Yaqian Han,Kunyu Yang,Yongsheng Li,Jun Yang,Zhenming Fu,Gang Chen,L. Chen,Ningning Zhou,Ting Zhou,Yaxiong Zhang,Huaqiang Zhou,Qianwen Liu
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (7): 901-911 被引量:35
标识
DOI:10.1016/s1470-2045(24)00159-1
摘要

Background Antibody–drug conjugates have promising clinical activity in the treatment of solid tumours. BL-B01D1 is a first-in-class EGFR–HER3 bispecific antibody–drug conjugate. We aimed to assess the safety and preliminary antitumour activity of BL-B01D1 in patients with locally advanced or metastatic solid tumours. Methods This first-in-human, open-label, multicentre, dose-escalation and dose-expansion phase 1 trial was conducted in seven hospitals in China, enrolling patients aged 18–75 years (dose escalation; phase 1a) or older than 18 years (dose expansion; phase 1b), with a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance status of 0–1, and histologically or cytologically confirmed locally advanced or metastatic solid tumours that had progressed on current standard treatment. In the phase 1a i3+3 design, patients received intravenous BL-B01D1 at three different schedules: 0·27 mg/kg, 1·5 mg/kg, and 3·0 mg/kg weekly; 2·5 mg/kg, 3·0 mg/kg, and 3·5 mg/kg on days 1 and 8 of each cycle every 3 weeks; or 5·0 mg/kg and 6·0 mg/kg on day 1 of each cycle every 3 weeks. The primary objectives of phase 1a were to identify the safety, maximum tolerated dose, and dose-limiting toxicity. In phase 1b, patients were treated in two schedules: 2·5 and 3·0 mg/kg on days 1 and 8 every 3 weeks, or 4·5, 5·0, and 6·0 mg/kg on day 1 every 3 weeks. The primary objectives of phase 1b were to assess the safety and recommended phase 2 dose of BL-B01D1, and objective response rate was a key secondary endpoint. Safety was analysed in all patients with safety records who received at least one dose of BL-B01D1. Antitumour activity was assessed in the activity analysis set which included all patients who received at least one dose of BL-B01D1 every 3 weeks. This trial is registered with China Drug Trials, CTR20212923, and ClinicalTrials.gov, NCT05194982, and recruitment is ongoing. Findings Between Dec 8, 2021, and March 13, 2023, 195 patients (133 [65%] men and 62 [32%] women; 25 in phase 1a and 170 in phase 1b) were consecutively enrolled, including 113 with non-small-cell lung cancer, 42 with nasopharyngeal carcinomas, 13 with small-cell lung cancer, 25 with head and neck squamous cell carcinoma, one with thymic squamous cell carcinoma, and one with submandibular lymphoepithelioma-like carcinoma. In phase 1a, four dose-limiting toxicities were observed (two at 3·0 mg/kg weekly and two at 3·5 mg/kg on days 1 and 8 every 3 weeks; all were febrile neutropenia), thus the maximum tolerated dose was reached at 3·0 mg/kg on days 1 and 8 every 3 weeks and 6·0 mg/kg on day 1 every 3 weeks. Grade 3 or worse treatment-related adverse events occurred in 139 (71%) of 195 patients; the most common of which were neutropenia (91 [47%]), anaemia (76 [39%]), leukopenia (76 [39%]), and thrombocytopenia (63 [32%]). 52 (27%) patients had a dose reduction and five (3%) patients discontinued treatment due to treatment-related adverse events. One patient was reported as having interstitial lung disease. Treatment-related deaths occurred in three (2%) patients (one due to pneumonia, one due to septic shock, and one due to myelosuppression). In 174 patients evaluated for activity, median follow-up was 6·9 months (IQR 4·5–8·9) and 60 (34%; 95% CI 27–42) patients had an objective response. Interpretation Our results suggest that BL-B01D1 has preliminary antitumour activity in extensively and heavily treated advanced solid tumours with an acceptable safety profile. Based on the safety and antitumour activity data from both phase 1a and 1b, 2·5 mg/kg on days 1 and 8 every 3 weeks was selected as the recommended phase 2 dose in Chinese patients. Funding Sichuan Baili Pharmaceutical. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
MMZ完成签到 ,获得积分10
2秒前
qianlan发布了新的文献求助10
2秒前
yemeiyu完成签到,获得积分10
3秒前
凶狠的谷蓝完成签到,获得积分10
3秒前
rzzzz完成签到,获得积分20
3秒前
Future发布了新的文献求助10
3秒前
Yue发布了新的文献求助10
4秒前
科研小桶发布了新的文献求助10
5秒前
18°N天水色完成签到,获得积分10
6秒前
6秒前
zpy完成签到,获得积分10
7秒前
dddd完成签到,获得积分10
7秒前
许哲完成签到,获得积分10
8秒前
8秒前
qianlan完成签到,获得积分10
8秒前
8秒前
汉堡包应助yff采纳,获得10
9秒前
10秒前
王嘉玮发布了新的文献求助10
10秒前
浅斟低唱发布了新的文献求助10
13秒前
斯文败类应助姜姜采纳,获得10
13秒前
豌豆射手发布了新的文献求助30
15秒前
科研小桶完成签到,获得积分20
19秒前
Lisa完成签到 ,获得积分10
19秒前
bogula1112完成签到 ,获得积分10
22秒前
ysysljj应助科研通管家采纳,获得10
24秒前
李爱国应助科研通管家采纳,获得10
24秒前
慕青应助科研通管家采纳,获得20
24秒前
ysysljj应助科研通管家采纳,获得30
24秒前
NexusExplorer应助科研通管家采纳,获得10
24秒前
今后应助科研通管家采纳,获得10
24秒前
24秒前
24秒前
24秒前
小蘑菇应助聪慧的盼夏采纳,获得10
25秒前
白白完成签到 ,获得积分10
26秒前
王嘉玮完成签到,获得积分10
27秒前
Bio应助www采纳,获得30
27秒前
27秒前
高分求助中
【重要!!请各位用户详细阅读此贴】科研通的精品贴汇总(请勿应助) 10000
Genomic signature of non-random mating in human complex traits 2000
Semantics for Latin: An Introduction 1099
醤油醸造の最新の技術と研究 1000
Plutonium Handbook 1000
Three plays : drama 1000
Robot-supported joining of reinforcement textiles with one-sided sewing heads 640
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4109721
求助须知:如何正确求助?哪些是违规求助? 3648056
关于积分的说明 11555522
捐赠科研通 3353801
什么是DOI,文献DOI怎么找? 1842442
邀请新用户注册赠送积分活动 908829
科研通“疑难数据库(出版商)”最低求助积分说明 825745